Clinical Trials · NCT03018028
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 243
- Start date
- Jan 2017
- Locations
- 16 sites, Japan
- Primary endpoint
- Change in HbA1c (Week 26)